Clifford Chance advises Vitruvian Partners and 65 Equity Partners on strategic investment in UltraGreen.ai

Global law firm Clifford Chance has advised Vitruvian Partners and 65 Equity Partners on their anchor investment in UltraGreen.ai, a global leader in surgical imaging and diagnostics, at an entry equity valuation of US$1.3 billion.

Singapore-headquartered UltraGreen.ai, through its subsidiary Diagnostic Green, is the world’s largest provider of indocyanine green (ICG), a key imaging agent used in over 90% of fluorescence-guided surgery procedures globally. The transaction marks a strategic partnership for UltraGreen.ai, enabling it to leverage the deep expertise of established international investors to scale healthcare technologies across global markets as it continues strategic expansion and diversification.

The Clifford Chance team consisted of partner Tom Lin, counsel Ivan Chan, and associates Audrey Siew, Denzyl Ang, and Yuqian Zhang. Partners Stephen Reese and Alex Walker, and associates Molly Margiotta and Isabella Savage, in London advised on the IP and healthcare aspects of the transaction. Partner Renee Latour, counsel Aniko Adam and associate David Harris advised Vitruvian on antitrust and FDI matters.